Literature DB >> 16647122

Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide.

Matthew S Benz1, Thomas A Albini, Eric R Holz, Rohit R Lakhanpal, Andrew C Westfall, Mohan N Iyer, Petros E Carvounis.   

Abstract

OBJECTIVE: To describe the natural history of intraocular pressure (IOP) within the first 30 minutes after intravitreal injection of triamcinolone acetonide (TA).
DESIGN: Prospective, interventional, consecutive case series. PARTICIPANTS: Thirty-eight consecutive patients who met inclusion and exclusion criteria and underwent intravitreal injection of 0.1 ml (4 mg) of TA were studied.
METHODS: Intraocular pressure was measured by Goldmann applanation tonometry at baseline; immediately after injection; and at 2, 5, 10, 20, and 30 minutes after injection. MAIN OUTCOME MEASURES: Intraocular pressure measurements at baseline; immediately after intravitreal injection; and 2, 5, 10, 20, and 30 minutes after injection, and percentage of patients with IOP < or = 24 mmHg at 30 minutes.
RESULTS: Patients who did not experience vitreous reflux (30/38 [78.9%]) at the site of injection had a significant initial elevation of IOP that rapidly normalized. Patients who experienced vitreous reflux (8/38 [21.1%]) at the site of injection had either no change in IOP or a small drop in IOP that rapidly normalized. The IOP measured in millimeters of mercury immediately after injection (45.9 [no reflux], 12.6 [reflux]), 2 minutes after injection (39.9 [no reflux], 13.5 [reflux]), 5 minutes after injection (33.3 [no reflux], 13.8 [reflux]), 10 minutes after injection (26.4 [no reflux], 15.1 [reflux]), and 20 minutes after injection (21.8 [no reflux], 15.0 [reflux]) showed a statistically significant difference between the 2 groups. The difference in IOP between the 2 groups was not significant at baseline or 30 minutes after injection. At 30 minutes, 90% (95% confidence interval, 85.8%-95.2%) of patients without vitreous reflux had an IOP < 24 mmHg.
CONCLUSIONS: Patients undergoing intravitreal injection of TA with no vitreous reflux have a risk of short-term elevation of IOP that rapidly normalizes over 30 minutes. In patients with vitreous reflux after the injection, the IOP declines immediately after injection and rapidly normalizes over 10 minutes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647122     DOI: 10.1016/j.ophtha.2005.10.061

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  34 in total

1.  Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique.

Authors:  Kyu-Seop Kim; Donghyun Jee
Journal:  Jpn J Ophthalmol       Date:  2011-09-23       Impact factor: 2.447

2.  Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle.

Authors:  Katrin Lorenz; Isabella Zwiener; Alireza Mirshahi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-21       Impact factor: 3.117

Review 3.  [Intravitreal injection. Monitoring to avoid postoperative complications].

Authors:  C H Meyer; F Ziemssen; H Heimann
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

4.  Particle-stabilized emulsion droplets for gravity-mediated targeting in the posterior segment of the eye.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Adv Healthc Mater       Date:  2014-03-20       Impact factor: 9.933

5.  Volume and composition of reflux after intravitreal injection.

Authors:  Frank L Brodie; Jason Ruggiero; Devon H Ghodasra; James Z Hui; Brian L VanderBeek; Alexander J Brucker
Journal:  Retina       Date:  2014-07       Impact factor: 4.256

6.  Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.

Authors:  Masoud Soheilian; Saeed Karimi; Talieh Montahae; Homayoun Nikkhah; Seyed Aliasghar Mosavi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-14       Impact factor: 3.117

7.  Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding.

Authors:  Matthew D Karl; Jasmine H Francis; Saipriya Iyer; Brian Marr; David H Abramson
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2017-01-17       Impact factor: 1.402

Review 8.  The suprachoroidal space as a route of administration to the posterior segment of the eye.

Authors:  Bryce Chiang; Jae Hwan Jung; Mark R Prausnitz
Journal:  Adv Drug Deliv Rev       Date:  2018-03-12       Impact factor: 15.470

Review 9.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

10.  Intraocular pressure effect of anti-vascular endothelial growth factor injection for aggressive posterior retinopathy of prematurity.

Authors:  Ozdemir Ozdemir; Aysegul Arman; Cuneyt Tayman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-21       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.